Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corcept Therapeutics (CORT) Long-Term Investments (2017 - 2025)

Historic Long-Term Investments for Corcept Therapeutics (CORT) over the last 9 years, with Q3 2025 value amounting to $102.6 million.

  • Corcept Therapeutics' Long-Term Investments fell 3870.24% to $102.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $102.6 million, marking a year-over-year decrease of 3870.24%. This contributed to the annual value of $219.8 million for FY2024, which is 28448.13% up from last year.
  • As of Q3 2025, Corcept Therapeutics' Long-Term Investments stood at $102.6 million, which was down 3870.24% from $172.8 million recorded in Q2 2025.
  • Corcept Therapeutics' 5-year Long-Term Investments high stood at $248.0 million for Q1 2025, and its period low was $4.9 million during Q3 2022.
  • Moreover, its 5-year median value for Long-Term Investments was $81.8 million (2021), whereas its average is $91.8 million.
  • In the last 5 years, Corcept Therapeutics' Long-Term Investments skyrocketed by 232040.48% in 2021 and then crashed by 9634.28% in 2022.
  • Over the past 5 years, Corcept Therapeutics' Long-Term Investments (Quarter) stood at $112.3 million in 2021, then plummeted by 95.59% to $4.9 million in 2022, then soared by 1055.77% to $57.2 million in 2023, then soared by 284.48% to $219.8 million in 2024, then plummeted by 53.35% to $102.6 million in 2025.
  • Its last three reported values are $102.6 million in Q3 2025, $172.8 million for Q2 2025, and $248.0 million during Q1 2025.